Breathe Well Live Well
|
New data from Boehringer Ingelheim's tiotropium Respimat Phase III UniTinA …
News-Medical.net These were the main findings from a new subset of data from the Phase III UniTinA-asthma® programme presented for the first time today at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Antonio, Texas. Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic … |
View full post on asthma – Google News
|
Phase III results: tiotropium* Respimat® is effective in symptomatic asthma …
Business Wire (press release) SAN ANTONIO, Texas–(BUSINESS WIRE)–Tiotropium delivered once daily via Respimat™ significantly improved lung function and reduced asthma exacerbations in patients who remain symptomatic despite treatment with at least ICS†/LABA‡, irrespective … Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic … |
View full post on asthma – Google News
|
INVION LTD : Invion announces initiation of phase II asthma study
4-traders Invion Limited (ASX:IVX), a clinical-stage drug development company targeting chronic inflammation, today announced the initiation of "NIMA", a phase II clinical trial that is funded by the US National Institute of Allergy and Infectious Diseases … |
View full post on asthma – Google News
 MENAFN.COM |
Invion starts second phase trial for asthma treatment
MENAFN.COM (MENAFN – ProactiveInvestors – Australia) Invion (ASX: IVX) has initiated the phase II "NIMA" clinical trial to investigate the use of INV102 in patients with mild asthma. The trail, which is funded by the U.S. National Institute of Allergy and … |
View full post on asthma – Google News
 Proactive Investors Australia |
Invion starts second phase trial for asthma treatment
Proactive Investors Australia Invion (ASX: IVX) has initiated the phase II “NIMA” clinical trial to investigate the use of INV102 in patients with mild asthma. The trail, which is funded by the U.S. National Institute of Allergy and Infectious Diseases through a cooperative … |
View full post on asthma – Google News
|
Dynavax Technologies to commence Phase I asthma studies
Equities.com Comtex News Network. Nov 02, 2012 (Datamonitor via COMTEX) — Dynavax Technologies Corporation, a biopharmaceutical company, has announced that it will advance AZD1419, a second-generation TLR-9 agonist for asthma, into Phase I clinical studies. |
View full post on asthma – Google News
|
Dynavax to Initiate Phase 1 Studies For TLR-9 Agonist For Asthma
Benzinga Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will advance AZD1419, a proprietary second-generation TLR-9 agonist for asthma, into Phase 1 clinical studies. Development expenses will be fully funded by AstraZeneca under … |
View full post on asthma – Google News
|
GlaxoSmithKline initiates Phase III refractory asthma program
Equities.com The Phase III program includes two key studies: MEA115588: A 32-week multicenter, randomized, double-blind, double-dummy, placebo-controlled study in patients with severe uncontrolled refractory asthma. The primary endpoint of the study is to evaluate … Glaxo Starting Late-Stage Study of Asthma Drug GlaxoSmithKline starts final-stage tests on severe asthma drug GSK takes severe asthma antibody into phase III |
View full post on asthma – Google News
|
KaloBios commences KB003 Phase 2 trial in severe asthma
News-Medical.net KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of KB003, the company's anti-GM-CSF Humaneered monoclonal antibody, in subjects with severe asthma … |
View full post on asthma – Google News
|
Rigel commences two Phase II allergic asthma and DLE studies
Equities.com Approximately 270 adults with allergic asthma will be randomized into the three arms of this Phase II clinical study of R343, called SITAR, or SYK Inhibition for Treatment of Asthma with R343, for eight weeks of treatment with either of two different … |
View full post on asthma – Google News